Modulation of recombinant and native neuronal SK channels by the neuroprotective drug riluzole.
about
Selective positive modulation of the SK3 and SK2 subtypes of small conductance Ca2+-activated K+ channelsPrecision medicine in spinocerebellar ataxias: treatment based on common mechanisms of diseaseCa(2+)-activated K+ channels: molecular determinants and function of the SK familyThe neuroprotective drug riluzole acts via small conductance Ca2+-activated K+ channels to ameliorate defects in spinal muscular atrophy modelsPharmacological gating modulation of small- and intermediate-conductance Ca(2+)-activated K(+) channels (KCa2.x and KCa3.1)Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressureMolecular and cellular basis of small--and intermediate-conductance, calcium-activated potassium channel function in the brain.The Sur1-Trpm4 Channel in Spinal Cord InjuryConserved genes act as modifiers of invertebrate SMN loss of function defectsA review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?Selective activation of KCa3.1 and CRAC channels by P2Y2 receptors promotes Ca(2+) signaling, store refilling and migration of rat microglial cellsTargeting the Small- and Intermediate-Conductance Ca-Activated Potassium Channels: The Drug-Binding Pocket at the Channel/Calmodulin InterfaceComparative effects of glibenclamide and riluzole in a rat model of severe cervical spinal cord injury.Effect of prolonged riluzole exposure on cultured motoneurons in a mouse model of ALS.Small-conductance calcium-activated potassium (SK) channels in the amygdala mediate pain-inhibiting effects of clinically available riluzole in a rat model of arthritis painEnhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia.Trafficking of intermediate (KCa3.1) and small (KCa2.x) conductance, Ca(2+)-activated K(+) channels: a novel target for medicinal chemistry efforts?Protective Roles for Potassium SK/K(Ca)2 Channels in Microglia and Neurons.K+ channel modulators for the treatment of neurological disorders and autoimmune diseasesEndothelial Ca+-activated K+ channels in normal and impaired EDHF-dilator responses--relevance to cardiovascular pathologies and drug discoveryA new pharmacological role for donepezil: attenuation of morphine-induced tolerance and apoptosis in rat central nervous system.Epigenetic mechanisms: critical contributors to long-term memory formation.K(Ca)2 and k(ca)3 channels in learning and memory processes, and neurodegeneration.Glutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approach.Treatment of cerebellar ataxia.Emerging therapies in Friedreich's ataxia.Microglial SK3 and SK4 currents and activation state are modulated by the neuroprotective drug, riluzole.Swelling activated Cl- channels in microglia: Biophysics, pharmacology and role in glutamate releaseInto the depths of ataxia.The modulation of two motor behaviors by persistent sodium currents in Xenopus laevis tadpoles.Immunofluorescence-based assay to identify modulators of the number of plasma membrane KCa3.1 channelsPacemaker and plateau potentials shape output of a developing locomotor networkComputational insights into the neuroprotective action of riluzole on 3-acetylpyridine-induced ataxia in rats.Pre- and postsynaptic mechanisms underlying inhibition of hypoglossal motor neuron excitability by riluzole.Acid-sensitive two-pore domain potassium (K2P) channels in mouse taste buds.Increased persistent Na(+) current and its effect on excitability in motoneurones cultured from mutant SOD1 mice.A transitional period of Ca2+-dependent spike afterdepolarization and bursting in developing rat CA1 pyramidal cells.Spike Ca2+ influx upmodulates the spike afterdepolarization and bursting via intracellular inhibition of KV7/M channels.Axo-somatic and apical dendritic Kv7/M channels differentially regulate the intrinsic excitability of adult rat CA1 pyramidal cells.Assessing the efficacy of specific cerebellomodulatory drugs for use as therapy for spinocerebellar ataxia type 1.
P2860
Q24564966-0562DB6E-8473-49D3-8080-D290F087EF97Q26764958-114327C1-6F5E-4607-8128-8754A97C0B06Q28283065-34ED4A46-581E-4378-B3B8-F815C379DA03Q28288745-AB1AED17-5E9E-40CB-9FC6-E4B4D05B6F59Q28833834-42F3A1E4-C340-4EAA-8480-AC88949D6CB8Q33379783-17F89841-282F-4E65-B44D-FC99ABF4B911Q33560844-D8240568-F712-4208-AF85-455B1BDACA24Q33602457-89F23E46-0A7C-42A0-833D-28BAE0FAF3E4Q33760559-EBCFF417-E2CD-4337-8E4C-FFA688BA4B06Q34104378-2765E4ED-F48F-42DE-8FD0-0BA2DC87FEBFQ34689609-0F057C1E-DB62-4CA6-BD11-A3B258E6657BQ35329866-F22278EE-D36F-4E61-A047-848AE0F2A78AQ35737505-5CEA8B5A-84F1-4CC4-953D-709064DBF44EQ35951394-A51F6AE6-A40D-411C-BE34-BE6166E38CD3Q36001934-12E92561-77B9-40E0-89F8-C493D83D2650Q36056879-A7AC5AD0-26A7-4010-ACCF-EEE6671B25CCQ36269118-A4A1C83E-D7A3-4E8F-97E4-7ABA8E431C2EQ36421908-183F2A1A-2BF8-40D1-8F8D-A1F73A692AF5Q37162392-F98B4A44-F165-42B8-B6D8-A57B47F42E98Q37255287-B1093296-98AE-4E71-97DA-5604B0A8C166Q37531862-030FA7C5-FC4E-4B1B-AB3B-FC3484E1E197Q37963238-1B86E078-3A37-441F-95F2-492A2D1EB19EQ38018945-9A3EE599-3F15-4842-9DAC-F3DD8662857EQ38154625-49ADD4A2-26CA-4ECB-9605-B388F9FF2696Q38269097-0B9A5745-7436-4683-9F6D-A30E5B81F11CQ38648895-96907B58-9057-4819-9D86-CCABC095C3E9Q39360213-C4DB4E07-5A46-4AB1-A72E-D5AF8C0F3936Q39621024-3882A7DD-0B56-4E4F-A941-776AF6C888C0Q40553739-661E9B76-16B6-4E51-AA9F-3C0801D2DF80Q40981371-E6D88431-BA8A-480C-B41E-C53066335D85Q41493798-5999803B-493A-4EF5-9D5B-FA930ECEB1EEQ42418404-C00DEBF9-B463-46E5-B730-CBA117FF0C0DQ43089818-EF683942-B876-4907-8B59-29820E482958Q44652546-9AA30B15-4616-4D16-83C2-1A7F559FD1D5Q44894463-A061C151-3A3C-45C5-B23C-55ED84BC4579Q45223589-DA3A5A6A-7408-40A9-AE8C-5930E8EF8A9CQ46513147-3612FEB9-7C04-40F0-850A-7A9F3CD0F878Q46813852-1D491301-F4AD-4E1A-9643-F9370BD758E7Q46958265-D09C252D-E20F-4E6E-8D7A-889B24038A52Q46980157-44D46673-6C8F-4506-8813-27240B0D8093
P2860
Modulation of recombinant and native neuronal SK channels by the neuroprotective drug riluzole.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Modulation of recombinant and ...... neuroprotective drug riluzole.
@en
type
label
Modulation of recombinant and ...... neuroprotective drug riluzole.
@en
prefLabel
Modulation of recombinant and ...... neuroprotective drug riluzole.
@en
P2093
P1476
Modulation of recombinant and ...... neuroprotective drug riluzole.
@en
P2093
John C Dreixler
Jonathan J Couey
Khaled M Houamed
Ying-Jun Cao
P356
10.1016/S0014-2999(02)01987-8
P407
P577
2002-08-01T00:00:00Z